spironolactone has been researched along with Chronic Kidney Diseases in 90 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These observations support a putative benefit of spironolactone treatment in CKD-associated vascular calcification." | 9.41 | Protective effects of spironolactone on vascular calcification in chronic kidney disease. ( Alesutan, I; Auer, T; Buehling, SS; Degenhart, G; Feger, M; Grebe, S; Hammer, F; Hauser, T; Krane, V; Lang, F; Malzahn, U; Masyout, J; Pasch, A; Tuffaha, R; Voelkl, J; Wanner, C, 2021) |
| "Consistent with the overall AMBER trial results, this pre-specified subgroup analysis in patients with HF, resistant hypertension and advanced chronic kidney disease demonstrated that patiromer enabled more persistent use of spironolactone by reducing the risk of hyperkalaemia." | 9.34 | Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. ( Ackourey, G; Agarwal, R; Arthur, S; Mayo, MR; Rossignol, P; Warren, S; White, WB; Williams, B, 2020) |
| "In patients with resistant hypertension and chronic kidney disease, patiromer enabled more patients to continue treatment with spironolactone with less hyperkalaemia." | 9.30 | Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. ( Agarwal, R; Garza, D; Ma, J; Mayo, MR; Romero, A; Rossignol, P; Warren, S; White, WB; Williams, B, 2019) |
| "The purpose of this study was to evaluate the effects of spironolactone on dialysis patients with refractory hypertension and possible adverse effects." | 9.19 | Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. ( Chen, J; Ni, X; Wu, F; Xia, M; Ying, G; Zhang, J; Zhang, P, 2014) |
| "Addition of low-dose eplerenone to renin-angiotensin system inhibitors might have renoprotective effects through reduction of albuminuria in hypertensive patients with non-diabetic chronic kidney disease, without serious safety concerns." | 9.19 | Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. ( Ando, K; Arakawa, Y; Fujita, T; Kaname, S; Ohtsu, H; Uchida, S, 2014) |
| "0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF." | 9.17 | Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). ( Eschalier, R; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Rossignol, P; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2013) |
| "To study the effects of addition of spironolactone to angiotensin-converting enzyme (ACE) inhibition or angiotensin II (AngII) receptor antagonism on proteinuria, blood pressure (BP) and renal function in overt type 2 diabetic nephropathy." | 9.12 | Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. ( Baggen, RG; Boomsma, F; Lindemans, A; Pauli, S; Poldermans, D; van den Meiracker, AH; Vulto, AG, 2006) |
| " In the present prospective randomized open-label study, we evaluated the effects of spironolactone (25 mg/day for 1 year) on proteinuria and estimated glomerular filtration rate in 83 patients with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors and/or angiotensin type 1 receptor antagonists." | 9.12 | Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. ( Bianchi, S; Bigazzi, R; Campese, VM, 2006) |
| "The prevalence of hyperkalemia in adult patients taking spironolactone and ACEIs or ARBs is 11." | 7.79 | Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers. ( Chatsiricharoenkul, S; Monsomboon, A; Surabenjawong, U; Thunpiphat, N, 2013) |
| "It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors." | 7.79 | [Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013) |
| "We considered that RSD could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity." | 6.87 | Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. ( Chen, S; Hoye, NA; Kiuchi, MG; Pürerfellner, H, 2018) |
| "Vascular calcification is frequently found already in early stages of chronic kidney disease (CKD) patients and is associated with high cardiovascular risk." | 6.50 | Impact of aldosterone on osteoinductive signaling and vascular calcification. ( Alesutan, I; Lang, F; Ritz, E; Voelkl, J, 2014) |
| "Low-dose spironolactone administration reduced albuminuria without causing hyperkalemia." | 5.69 | Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes. ( Hiwatashi, D; Kawata, I; Koinuma, M; Komatsu, M; Miyamoto, T; Oiwa, A; Takeda, T; Yamazaki, M, 2023) |
| "Spironolactone was initiated prior to admission (PTA) for 54." | 5.62 | Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease. ( Armbruster, AL; Buckallew, AR; Mbachu, G; Miller, W; Seltzer, JR; Tellor, KB; Watson, R; Whitlock, C, 2021) |
| "Spironolactone has been shown to reduce cardiovascular death in patients with mild-to-moderate chronic kidney disease (CKD), but its risks and benefits in advanced CKD remain unsettled." | 5.46 | Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study. ( Chen, YH; Hsu, CC; Hung, SC; Kuo, KL; Liu, JS; Tarng, DC; Tseng, WC, 2017) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 5.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| "These observations support a putative benefit of spironolactone treatment in CKD-associated vascular calcification." | 5.41 | Protective effects of spironolactone on vascular calcification in chronic kidney disease. ( Alesutan, I; Auer, T; Buehling, SS; Degenhart, G; Feger, M; Grebe, S; Hammer, F; Hauser, T; Krane, V; Lang, F; Malzahn, U; Masyout, J; Pasch, A; Tuffaha, R; Voelkl, J; Wanner, C, 2021) |
| "Treatment with spironolactone either before or after ischemia prevented subsequent CKD by avoiding the activation of fibrotic and inflammatory pathways." | 5.39 | Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. ( Barrera-Chimal, J; Bobadilla, NA; Gamba, G; Pérez-Villalva, R; Reyna, J; Rodríguez-Romo, R; Uribe, N, 2013) |
| "Consistent with the overall AMBER trial results, this pre-specified subgroup analysis in patients with HF, resistant hypertension and advanced chronic kidney disease demonstrated that patiromer enabled more persistent use of spironolactone by reducing the risk of hyperkalaemia." | 5.34 | Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. ( Ackourey, G; Agarwal, R; Arthur, S; Mayo, MR; Rossignol, P; Warren, S; White, WB; Williams, B, 2020) |
| "In patients with resistant hypertension and chronic kidney disease, patiromer enabled more patients to continue treatment with spironolactone with less hyperkalaemia." | 5.30 | Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. ( Agarwal, R; Garza, D; Ma, J; Mayo, MR; Romero, A; Rossignol, P; Warren, S; White, WB; Williams, B, 2019) |
| "Enablement of more persistent spironolactone use with newer potassium-binding agents, the clinical development of novel nonsteroidal MRAs with a more favourable benefit-risk profile and the recently proven blood pressure lowering action of chlorthalidone are three therapeutic opportunities for more effective management of hypertension in high-risk patients with advanced CKD." | 5.22 | Management of hypertension in advanced kidney disease. ( Agarwal, R; Georgianos, PI, 2022) |
| " Steroidal mineralocorticoid receptor antagonists (MRAs - eplerenone and spironolactone) reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF)." | 5.22 | Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. ( Armani, A; Caprio, M; Infante, M; Marzolla, V; Rizzo, M, 2022) |
| "In short-term studies in patients with CKD and reduced ejection heart failure, with or without T2D, finerenone 20 mg appears to have a better renal outcome compared with spironolactone and a better mortality outcome compared with eplerenone, with significantly lesser hyperkalemia compared to both spironolactone and finerenone." | 5.22 | Finerenone in diabetic kidney disease: A systematic review and critical appraisal. ( Misra, A; Singh, A; Singh, AK; Singh, R, 2022) |
| "The purpose of this study was to evaluate the effects of spironolactone on dialysis patients with refractory hypertension and possible adverse effects." | 5.19 | Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. ( Chen, J; Ni, X; Wu, F; Xia, M; Ying, G; Zhang, J; Zhang, P, 2014) |
| "Addition of low-dose eplerenone to renin-angiotensin system inhibitors might have renoprotective effects through reduction of albuminuria in hypertensive patients with non-diabetic chronic kidney disease, without serious safety concerns." | 5.19 | Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. ( Ando, K; Arakawa, Y; Fujita, T; Kaname, S; Ohtsu, H; Uchida, S, 2014) |
| "0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF." | 5.17 | Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). ( Eschalier, R; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Rossignol, P; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2013) |
| " The aim was to compare the effects on albuminuria of the therapy with either: (i) telmisartan 80 mg and aliskiren 300 mg, (ii) telmisartan 80 mg and eplerenone 50 mg, (iii) telmisartan 160 mg as monotherapy." | 5.16 | The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?. ( Bednarski, R; Donderski, R; Heleniak, Z; Lizakowski, S; Manitius, J; Przybylska, M; Renke, M; Rutkowski, B; Rutkowski, P; Sulikowska, B; Tylicki, L, 2012) |
| "To study the effects of addition of spironolactone to angiotensin-converting enzyme (ACE) inhibition or angiotensin II (AngII) receptor antagonism on proteinuria, blood pressure (BP) and renal function in overt type 2 diabetic nephropathy." | 5.12 | Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. ( Baggen, RG; Boomsma, F; Lindemans, A; Pauli, S; Poldermans, D; van den Meiracker, AH; Vulto, AG, 2006) |
| " In the present prospective randomized open-label study, we evaluated the effects of spironolactone (25 mg/day for 1 year) on proteinuria and estimated glomerular filtration rate in 83 patients with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors and/or angiotensin type 1 receptor antagonists." | 5.12 | Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. ( Bianchi, S; Bigazzi, R; Campese, VM, 2006) |
| " Notably, spironolactone treatment concomitantly suppressed the release of Bsg-bearing EVs in correlation with decreased albuminuria." | 4.31 | Basigin is released in extracellular vesicles derived from the renal tubular epithelium in response to albuminuria. ( Kadomatsu, K; Kato, N; Kato, S; Kosugi, T; Maeda, K; Maruyama, S; Ryuge, A; Sato, Y; Seko, H; Sugimura, M; Watanabe, T, 2023) |
| "Although matching aligned key demographic and clinical characteristics of the cohorts, a significantly greater proportion of spironolactone users than non-users had oedema, proteinuria, and cardiovascular disease at baseline (P < 0." | 3.96 | Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users. ( Blankenburg, M; Fett, AK; Gay, A; Griner, RG; Kovesdy, CP, 2020) |
| " Compared with placebo, across all eGFR categories, spironolactone was associated with lower relative risk for the primary efficacy outcome and for hypokalemia, but higher relative risk for hyperkalemia, worsening renal function, and drug discontinuation." | 3.91 | Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. ( Beldhuis, IE; Claggett, B; Damman, K; Desai, AS; Fang, JC; Lewis, EF; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Voors, AA, 2019) |
| "Longstanding primary aldosteronism (PA) has deleterious effects on renal function, often masked until treatment (adrenalectomy or spironolactone) is initiated." | 3.85 | Effects of Treating Primary Aldosteronism on Renal Function. ( Deinum, J; Kramers, BJ; Kramers, C; Lenders, JW, 2017) |
| "A total of 6,575 patients with hypertension treated between January 1, 2000, and November 30, 2012, were evaluated for the safety of an aldosterone-blocking agent (spironolactone) added to preexisting blood pressure-lowering regimens." | 3.80 | Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease. ( Gwoo, S; Jung, YS; Kim, YN; Rim, H; Shin, HS, 2014) |
| "It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors." | 3.79 | [Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013) |
| "The prevalence of hyperkalemia in adult patients taking spironolactone and ACEIs or ARBs is 11." | 3.79 | Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers. ( Chatsiricharoenkul, S; Monsomboon, A; Surabenjawong, U; Thunpiphat, N, 2013) |
| " A combination of short-term low-dose SPL and ARB is safe for patients with stage 1-3a CKD, but blood potassium must be regularly monitored." | 3.11 | Efficacy and safety of a low-sodium diet and spironolactone in patients with stage 1-3a chronic kidney disease: a pilot study. ( Chang, L; Chen, H; He, L; Tian, R; Wang, Y; Ye, X; Yu, D; Zhang, H; Zhu, B, 2022) |
| "Hypertension is very common and remains often poorly controlled in patients with chronic kidney disease (CKD)." | 3.01 | Hypertension in chronic kidney disease-treatment standard 2023. ( Agarwal, R; Georgianos, PI, 2023) |
| "We considered that RSD could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity." | 2.87 | Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. ( Chen, S; Hoye, NA; Kiuchi, MG; Pürerfellner, H, 2018) |
| "Approximately 40% of people with type 2 diabetes (T2D) also have chronic kidney disease (CKD), which substantially increases their risk of cardiovascular (CV)-related complications and mortality." | 2.82 | Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. ( Lerma, EV; Wilson, DJ, 2022) |
| "Spironolactone was well tolerated in selected patients with early stage CKD." | 2.77 | The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. ( Chue, CD; Edwards, NC; Ferro, CJ; Steeds, RP; Stewart, PM; Townend, JN, 2012) |
| "Aldosterone has emerged as an important mediator of disease progression and mortality in patients with chronic heart and kidney disease (CKD)." | 2.75 | The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. ( Edwards, NC; Ferro, CJ; Hammer, F; Hughes, BA; Steeds, RP; Stewart, PM; Townend, JN, 2010) |
| " In all patients, diuretics were administered according to a standardized dosing algorithm." | 2.73 | The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. ( Burnett, JC; Chen, HH; Frantz, RP; Hodge, DO; Karon, BL; Miller, WL; Owan, TE; Redfield, MM; Rodeheffer, RJ, 2008) |
| "Aldosterone also promotes collagen synthesis, which leads to increased arterial stiffness and elevation of blood pressure." | 2.53 | Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016. ( Duprez, DA; Epstein, M, 2016) |
| "Hypertension is the leading cause of early mortality in the world, and reduction of blood pressure can help to reduce that burden." | 2.53 | Update in Hypertension Therapy. ( Mankin, LA, 2016) |
| "19." | 2.53 | Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. ( Bomback, AS, 2016) |
| " The dose-response relationship for natriuresis with spironolactone has not been explored completely as to its combination therapy responses." | 2.50 | Aldosterone and volume management in hypertensive heart disease. ( Sica, DA, 2014) |
| "Vascular calcification is frequently found already in early stages of chronic kidney disease (CKD) patients and is associated with high cardiovascular risk." | 2.50 | Impact of aldosterone on osteoinductive signaling and vascular calcification. ( Alesutan, I; Lang, F; Ritz, E; Voelkl, J, 2014) |
| "Patients are diagnosed as having resistant hypertension when they have blood pressure readings that remain above goal despite the concomitant use of 3 optimally dosed antihypertensive agents from different classes, with 1 of the agents being a diuretic." | 2.48 | Evaluation and pharmacologic approach to patients with resistant hypertension. ( Adams, M; Bellone, JM; Rutecki, GW; Wright, BM, 2012) |
| "Spironolactone was initiated prior to admission (PTA) for 54." | 1.62 | Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease. ( Armbruster, AL; Buckallew, AR; Mbachu, G; Miller, W; Seltzer, JR; Tellor, KB; Watson, R; Whitlock, C, 2021) |
| "In conclusion, hypokalemia is extremely common in patients presenting with VT/VF, much more so than in patients with CHF alone." | 1.56 | Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study). ( Basil, A; Cooper, JM; Gangireddy, C; Greenberg, RM; Laslett, DB; Whitman, IR; Yesenosky, GA, 2020) |
| "We can treat hypertension more effectively by getting the blood pressure measurement right, understanding the link between albuminuria and hypertension, enabling the use of spironolactone to treat resistant hypertension through the use of drugs that bind potassium in the gut, and addressing the structural determinants of health." | 1.51 | Caring for individuals with hypertension in CKD, especially those with low education. ( Agarwal, R, 2019) |
| "Hypertension was reported in 70-92% of patients, irrespective of disease cohort or population." | 1.51 | Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. ( Blankenburg, M; Eisenring, S; Fett, AK; Gay, A; Haas, G, 2019) |
| "Hyperkalemia is associated with severe clinical outcomes and death in HF." | 1.48 | Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study. ( Adelborg, K; Egfjord, M; Egstrup, K; Garcia-Sanchez, R; Hasvold, P; Nicolaisen, SK; Pedersen, L; Sørensen, HT; Thomsen, RW, 2018) |
| "However, incidence of postoperative low cardiac output state (p < 0." | 1.48 | Preoperative aldosterone receptor blockade and outcomes of cardiac surgery in patients with chronic kidney disease . ( Bitran, D; Fink, D; Merin, O; Shavit, L; Silberman, S; Tauber, R, 2018) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 1.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| "Spironolactone has been shown to reduce cardiovascular death in patients with mild-to-moderate chronic kidney disease (CKD), but its risks and benefits in advanced CKD remain unsettled." | 1.46 | Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study. ( Chen, YH; Hsu, CC; Hung, SC; Kuo, KL; Liu, JS; Tarng, DC; Tseng, WC, 2017) |
| "The findings indicate that dosing errors were common among hospitalized patients with renal impairment." | 1.42 | Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. ( Getachew, H; Shibeshi, W; Tadesse, Y, 2015) |
| "Treatment with spironolactone either before or after ischemia prevented subsequent CKD by avoiding the activation of fibrotic and inflammatory pathways." | 1.39 | Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. ( Barrera-Chimal, J; Bobadilla, NA; Gamba, G; Pérez-Villalva, R; Reyna, J; Rodríguez-Romo, R; Uribe, N, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (6.67) | 29.6817 |
| 2010's | 57 (63.33) | 24.3611 |
| 2020's | 27 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hammer, F | 2 |
| Buehling, SS | 1 |
| Masyout, J | 1 |
| Malzahn, U | 1 |
| Hauser, T | 1 |
| Auer, T | 1 |
| Grebe, S | 1 |
| Feger, M | 2 |
| Tuffaha, R | 1 |
| Degenhart, G | 1 |
| Lang, F | 3 |
| Pasch, A | 1 |
| Alesutan, I | 3 |
| Wanner, C | 1 |
| Krane, V | 1 |
| Voelkl, J | 3 |
| Epstein, M | 2 |
| Pecoits-Filho, R | 1 |
| Clase, CM | 1 |
| Sood, MM | 1 |
| Kovesdy, CP | 2 |
| Mårup, FH | 1 |
| Peters, CD | 1 |
| Christensen, JH | 1 |
| Birn, H | 1 |
| Zhang, H | 1 |
| Zhu, B | 1 |
| Chang, L | 1 |
| Ye, X | 1 |
| Tian, R | 1 |
| He, L | 1 |
| Yu, D | 1 |
| Chen, H | 1 |
| Wang, Y | 1 |
| Agarwal, R | 9 |
| Rossignol, P | 8 |
| Budden, J | 1 |
| Mayo, MR | 5 |
| Arthur, S | 4 |
| Williams, B | 5 |
| White, WB | 5 |
| Georgianos, PI | 4 |
| Lerma, EV | 1 |
| Wilson, DJ | 1 |
| Pluquet, M | 1 |
| Kamel, S | 1 |
| Choukroun, G | 1 |
| Liabeuf, S | 1 |
| Laville, SM | 1 |
| Marzolla, V | 1 |
| Infante, M | 1 |
| Armani, A | 1 |
| Rizzo, M | 1 |
| Caprio, M | 1 |
| Singh, AK | 1 |
| Singh, A | 1 |
| Singh, R | 1 |
| Misra, A | 1 |
| Awadalla, A | 1 |
| Hamam, ET | 1 |
| El-Senduny, FF | 1 |
| Omar, NM | 1 |
| Mahdi, MR | 1 |
| Barakat, N | 1 |
| Ammar, OA | 1 |
| Hussein, AM | 1 |
| Shokeir, AA | 1 |
| Khirallah, SM | 1 |
| Oiwa, A | 1 |
| Hiwatashi, D | 1 |
| Takeda, T | 1 |
| Miyamoto, T | 1 |
| Kawata, I | 1 |
| Koinuma, M | 1 |
| Yamazaki, M | 1 |
| Komatsu, M | 2 |
| Ding, K | 1 |
| Li, Z | 1 |
| Lu, Y | 1 |
| Sun, L | 1 |
| Watanabe, T | 1 |
| Maeda, K | 1 |
| Kato, N | 1 |
| Seko, H | 1 |
| Sugimura, M | 1 |
| Sato, Y | 1 |
| Ryuge, A | 1 |
| Kato, S | 1 |
| Kadomatsu, K | 1 |
| Maruyama, S | 1 |
| Kosugi, T | 1 |
| Vaios, V | 1 |
| Karligkiotis, A | 1 |
| Georgianou, E | 1 |
| Liakopoulos, V | 1 |
| Gueiros, APS | 1 |
| Gueiros, JEB | 1 |
| Nóbrega, KT | 1 |
| Calado, EB | 1 |
| Matta, MCD | 1 |
| Torres, LC | 1 |
| Souza, ASR | 1 |
| Casarini, DE | 1 |
| Carvalho, AB | 1 |
| Romero, A | 2 |
| Garza, D | 2 |
| Warren, S | 3 |
| Ma, J | 1 |
| Ganesan, C | 1 |
| Pao, AC | 1 |
| Mikačić, I | 1 |
| Blankenburg, M | 2 |
| Fett, AK | 2 |
| Griner, RG | 1 |
| Gay, A | 2 |
| Ackourey, G | 1 |
| Laslett, DB | 1 |
| Cooper, JM | 1 |
| Greenberg, RM | 1 |
| Yesenosky, GA | 1 |
| Basil, A | 1 |
| Gangireddy, C | 1 |
| Whitman, IR | 1 |
| Ali, W | 1 |
| Bakris, G | 1 |
| Wan, N | 1 |
| Rahman, A | 1 |
| Nishiyama, A | 1 |
| O'Sullivan, ED | 1 |
| MacIntyre, IM | 1 |
| Buckallew, AR | 1 |
| Tellor, KB | 1 |
| Watson, R | 1 |
| Miller, W | 1 |
| Mbachu, G | 1 |
| Whitlock, C | 1 |
| Seltzer, JR | 1 |
| Armbruster, AL | 1 |
| Hasegawa, T | 1 |
| Nishiwaki, H | 1 |
| Ota, E | 1 |
| Levack, WM | 1 |
| Noma, H | 1 |
| Conrad, A | 1 |
| Tseng, WC | 1 |
| Liu, JS | 1 |
| Hung, SC | 1 |
| Kuo, KL | 1 |
| Chen, YH | 1 |
| Tarng, DC | 1 |
| Hsu, CC | 1 |
| Offman, R | 1 |
| Paden, A | 1 |
| Gwizdala, A | 1 |
| Reeves, JF | 1 |
| Donderski, R | 2 |
| Stróżecki, P | 1 |
| Sulikowska, B | 2 |
| Grajewska, M | 1 |
| Miśkowiec, I | 1 |
| Stefańska, A | 1 |
| Siódmiak, J | 1 |
| Odrowąż-Sypniewska, G | 1 |
| Manitius, J | 2 |
| Elseweidy, MM | 1 |
| Askar, ME | 1 |
| Elswefy, SE | 1 |
| Shawky, M | 1 |
| Shavit, L | 1 |
| Silberman, S | 1 |
| Tauber, R | 1 |
| Merin, O | 1 |
| Bitran, D | 1 |
| Fink, D | 1 |
| Kiuchi, MG | 1 |
| Chen, S | 1 |
| Hoye, NA | 1 |
| Pürerfellner, H | 1 |
| Pitt, B | 5 |
| Bamberg, K | 1 |
| Johansson, U | 1 |
| Edman, K | 1 |
| William-Olsson, L | 1 |
| Myhre, S | 1 |
| Gunnarsson, A | 1 |
| Geschwindner, S | 1 |
| Aagaard, A | 1 |
| Björnson Granqvist, A | 1 |
| Jaisser, F | 1 |
| Huang, Y | 1 |
| Granberg, KL | 1 |
| Jansson-Löfmark, R | 1 |
| Hartleib-Geschwindner, J | 1 |
| Thomsen, RW | 1 |
| Nicolaisen, SK | 1 |
| Hasvold, P | 1 |
| Garcia-Sanchez, R | 1 |
| Pedersen, L | 1 |
| Adelborg, K | 1 |
| Egfjord, M | 2 |
| Egstrup, K | 1 |
| Sørensen, HT | 1 |
| Tsujimoto, T | 1 |
| Kajio, H | 1 |
| Barrera-Chimal, J | 3 |
| Rocha, L | 1 |
| Amador-Martínez, I | 1 |
| Pérez-Villalva, R | 2 |
| González, R | 1 |
| Cortés-González, C | 1 |
| Uribe, N | 2 |
| Ramírez, V | 1 |
| Berman, N | 1 |
| Gamba, G | 2 |
| Bobadilla, NA | 3 |
| Beldhuis, IE | 1 |
| Myhre, PL | 1 |
| Claggett, B | 1 |
| Damman, K | 1 |
| Fang, JC | 1 |
| Lewis, EF | 1 |
| O'Meara, E | 1 |
| Shah, SJ | 1 |
| Voors, AA | 3 |
| Pfeffer, MA | 1 |
| Solomon, SD | 1 |
| Desai, AS | 1 |
| Ferreira, JP | 1 |
| Eisenring, S | 1 |
| Haas, G | 1 |
| Ocello, A | 1 |
| La Rosa, S | 1 |
| Fiorini, F | 1 |
| Randone, S | 1 |
| Maccarrone, R | 1 |
| Battaglia, G | 1 |
| Granata, A | 1 |
| Andreev, DA | 1 |
| Gappoeva, ZK | 1 |
| Sychev, DA | 1 |
| Giliarov, MIu | 1 |
| Boesby, L | 1 |
| Elung-Jensen, T | 1 |
| Strandgaard, S | 1 |
| Kamper, AL | 1 |
| Bart, BA | 1 |
| Nelson, S | 1 |
| Eschalier, R | 1 |
| McMurray, JJ | 1 |
| Swedberg, K | 1 |
| van Veldhuisen, DJ | 1 |
| Krum, H | 3 |
| Pocock, SJ | 1 |
| Shi, H | 1 |
| Vincent, J | 1 |
| Zannad, F | 3 |
| Cabrera, SE | 1 |
| Edwards, NC | 3 |
| Steeds, RP | 3 |
| Townend, JN | 4 |
| Ferro, CJ | 4 |
| Chou, YH | 1 |
| Lin, SL | 1 |
| Surabenjawong, U | 1 |
| Thunpiphat, N | 1 |
| Chatsiricharoenkul, S | 1 |
| Monsomboon, A | 1 |
| Mavrakanas, TA | 1 |
| Gariani, K | 1 |
| Martin, PY | 1 |
| Hill, NR | 1 |
| Lasserson, D | 1 |
| Thompson, B | 1 |
| Perera-Salazar, R | 1 |
| Wolstenholme, J | 1 |
| Bower, P | 1 |
| Blakeman, T | 1 |
| Fitzmaurice, D | 1 |
| Little, P | 1 |
| Feder, G | 1 |
| Qureshi, N | 1 |
| Taal, M | 1 |
| Townend, J | 1 |
| Ferro, C | 1 |
| McManus, R | 1 |
| Hobbs, FR | 1 |
| Hassan, M | 1 |
| Qureshi, W | 1 |
| Sroujieh, LS | 1 |
| Albashaireh, D | 1 |
| BouMalham, S | 1 |
| Liroff, M | 1 |
| Amjad, W | 1 |
| Khalid, F | 1 |
| Hadid, H | 1 |
| Alirhayim, Z | 1 |
| Sica, DA | 1 |
| Ni, X | 1 |
| Zhang, J | 1 |
| Zhang, P | 1 |
| Wu, F | 1 |
| Xia, M | 1 |
| Ying, G | 1 |
| Chen, J | 1 |
| Hosoya, K | 1 |
| Minakuchi, H | 1 |
| Wakino, S | 1 |
| Fujimura, K | 1 |
| Hasegawa, K | 1 |
| Yoshifuji, A | 1 |
| Futatsugi, K | 1 |
| Shinozuka, K | 1 |
| Washida, N | 1 |
| Kanda, T | 1 |
| Tokuyama, H | 1 |
| Hayashi, K | 1 |
| Itoh, H | 1 |
| Ritz, E | 1 |
| Ando, K | 1 |
| Ohtsu, H | 1 |
| Uchida, S | 1 |
| Kaname, S | 1 |
| Arakawa, Y | 1 |
| Fujita, T | 1 |
| Gwoo, S | 1 |
| Kim, YN | 1 |
| Shin, HS | 1 |
| Jung, YS | 1 |
| Rim, H | 1 |
| Anker, SD | 2 |
| Böhm, M | 2 |
| Gheorghiade, M | 2 |
| Køber, L | 2 |
| Maggioni, AP | 2 |
| Ponikowski, P | 2 |
| Nowack, C | 3 |
| Kim, SY | 3 |
| Pieper, A | 2 |
| Kimmeskamp-Kirschbaum, N | 2 |
| Filippatos, G | 2 |
| Tatsumoto, N | 1 |
| Yamada, S | 1 |
| Tokumoto, M | 1 |
| Eriguchi, M | 1 |
| Noguchi, H | 1 |
| Torisu, K | 1 |
| Tsuruya, K | 1 |
| Kitazono, T | 1 |
| Getachew, H | 1 |
| Tadesse, Y | 1 |
| Shibeshi, W | 1 |
| Bomback, AS | 2 |
| Duprez, DA | 1 |
| Ng, KP | 1 |
| Jain, P | 1 |
| Gill, PS | 1 |
| Heer, G | 1 |
| Freemantle, N | 1 |
| Greenfield, S | 1 |
| McManus, RJ | 1 |
| Sato, N | 1 |
| Ajioka, M | 1 |
| Yamada, T | 2 |
| Kato, M | 1 |
| Myoishi, M | 1 |
| Kolkhof, P | 2 |
| Shiga, T | 1 |
| Palombo, G | 1 |
| Mankin, LA | 1 |
| Kramers, BJ | 1 |
| Kramers, C | 1 |
| Lenders, JW | 1 |
| Deinum, J | 1 |
| Hoss, S | 1 |
| Elizur, Y | 1 |
| Luria, D | 1 |
| Keren, A | 1 |
| Lotan, C | 1 |
| Gotsman, I | 1 |
| Kshirsagar, AV | 1 |
| Klemmer, PJ | 1 |
| Sengul, E | 1 |
| Sahin, T | 1 |
| Sevin, E | 1 |
| Yilmaz, A | 1 |
| Maron, BA | 1 |
| Leopold, JA | 1 |
| Hughes, BA | 1 |
| Stewart, PM | 2 |
| Kristensen, KE | 1 |
| Chue, CD | 1 |
| Torigoe, K | 1 |
| Tamura, A | 1 |
| Kawano, Y | 1 |
| Shinozaki, K | 1 |
| Kotoku, M | 1 |
| Kadota, J | 1 |
| Adams, M | 1 |
| Bellone, JM | 1 |
| Wright, BM | 1 |
| Rutecki, GW | 1 |
| Rodríguez-Romo, R | 1 |
| Reyna, J | 1 |
| Tylicki, L | 1 |
| Lizakowski, S | 1 |
| Rutkowski, P | 1 |
| Renke, M | 1 |
| Heleniak, Z | 1 |
| Bednarski, R | 1 |
| Przybylska, M | 1 |
| Rutkowski, B | 1 |
| Leibrock, CB | 1 |
| Quintanilla-Martinez, L | 1 |
| Kuhn, V | 1 |
| Mia, S | 1 |
| Ahmed, MS | 1 |
| Rosenblatt, KP | 1 |
| Kuro-O, M | 1 |
| Bianchi, S | 1 |
| Bigazzi, R | 1 |
| Campese, VM | 2 |
| Park, J | 1 |
| van den Meiracker, AH | 1 |
| Baggen, RG | 1 |
| Pauli, S | 1 |
| Lindemans, A | 1 |
| Vulto, AG | 1 |
| Poldermans, D | 1 |
| Boomsma, F | 1 |
| Owan, TE | 1 |
| Chen, HH | 1 |
| Frantz, RP | 1 |
| Karon, BL | 1 |
| Miller, WL | 1 |
| Rodeheffer, RJ | 1 |
| Hodge, DO | 1 |
| Burnett, JC | 1 |
| Redfield, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients With Resistant Hypertension and Chronic Kidney Disease[NCT03071263] | Phase 2 | 295 participants (Actual) | Interventional | 2017-01-23 | Completed | ||
| A Randomized, Controlled Trial of L-arginine and Spironolactone in Dialysis-dependant End Stage Renal Disease[NCT01855334] | Phase 4 | 0 participants (Actual) | Interventional | 2013-09-30 | Withdrawn (stopped due to change of funding leading to major redesign) | ||
| Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients[NCT03314493] | Phase 3 | 33 participants (Actual) | Interventional | 2014-11-07 | Completed | ||
| Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies[NCT00277693] | Phase 4 | 0 participants | Interventional | Recruiting | |||
| Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease[NCT03020303] | Phase 3 | 2,750 participants (Anticipated) | Interventional | 2017-07-07 | Recruiting | ||
| [NCT01687699] | Phase 4 | 157 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Subjects With Severe Heart Failure and End-Stage Renal Disease on Hemodialysis: A Pilot Study to Assess Safety and Tolerability of Spironolactone[NCT00328809] | Phase 4 | 0 participants (Actual) | Interventional | 2013-06-30 | Withdrawn (stopped due to personnel shortage) | ||
| Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease (ESRD) (SPin-D) Trial[NCT02285920] | Phase 2 | 129 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Role of Renin Angiotensin Blockade in Peritoneal Fibrosis in Peritoneal Dialysis Patients[NCT00865449] | Phase 3 | 20 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients[NCT01128101] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-03-31 | Recruiting | ||
| Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Continuous Ambulatory Peritoneal Dialysis Patients: An Open-Label Randomized-Controlled Trial[NCT03953950] | Phase 4 | 84 participants (Anticipated) | Interventional | 2019-10-31 | Not yet recruiting | ||
| The Effects of Losartan and Spironolactone on Residual Renal Function Preservation in Peritoneal Dialysis Patients[NCT02190318] | 96 participants (Anticipated) | Interventional | 2013-11-30 | Recruiting | |||
| ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b[NCT01848639] | Phase 3 | 823 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months.[NCT02490904] | Phase 3 | 132 participants (Anticipated) | Interventional | 2016-10-19 | Active, not recruiting | ||
| Pilot Trial of Hemodialysis Patient Aldosterone antagoniSm With Eplerenone Trial[NCT01650012] | 158 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Phase II Trial to Evaluate the Efficacy and Safety of Spironolactone in Hemodialysis Patients[NCT01691053] | Phase 2 | 118 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Aldosterone Blockade in Chronic Kidney Disease. Influence on Arterial Stiffness and Kidney Function[NCT01100203] | Phase 3 | 54 participants (Actual) | Interventional | 2010-04-30 | Terminated (stopped due to It was not possible within the time frame to recruit the planned no. of patients.) | ||
| The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure[NCT00232180] | Phase 3 | 2,743 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Non-interventional, Multicenter, Observational Clinical Trial to Assess Eplerenone Treatment in Patients With Heart Failure.[NCT02344199] | 450 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia：A Multicenter Randomized Controlled Study[NCT05688579] | Phase 4 | 8,000 participants (Anticipated) | Interventional | 2023-04-16 | Enrolling by invitation | ||
| A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systo[NCT01807221] | Phase 2 | 1,066 participants (Actual) | Interventional | 2013-06-17 | Completed | ||
| A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction[NCT01955694] | Phase 2 | 72 participants (Actual) | Interventional | 2013-11-11 | Completed | ||
| Efficacy and Safety of Finerenone in Patients With Heart Failure With Reduced Ejection Fraction[NCT05974566] | 60 participants (Anticipated) | Observational | 2023-08-01 | Not yet recruiting | |||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Pilot Non Randomised Controlled Trial of Short Term Spironolactone Use for Prevention of Acute Kidney Injury After Cardiac Surgery[NCT02417896] | 150 participants (Anticipated) | Interventional | 2013-04-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
AOBP: Automated Office Blood Pressure SBP: Systolic Blood Pressure BP: Blood Pressure (NCT03071263)
Timeframe: From baseline to Week 12
| Intervention | mmHg (Mean) |
|---|---|
| Group 1 - Patiromer | -11.3 |
| Group 2 - Placebo | -11.0 |
AOBP SBP: Automated Office Systolic Blood Pressure (NCT03071263)
Timeframe: From baseline to Week 12
| Intervention | mmHg (Mean) |
|---|---|
| Group 1 - Patiromer | -11.3 |
| Group 2 - Placebo | -11.2 |
The proportion of subjects remaining on spironolactone at Week 12 will be compared between treatment groups (spironolactone/patiromer versus spironolactone/placebo). Subjects who discontinued from the study early or discontinued study spironolactone prior to Week 12, for any reason, were considered as not having remained on spironolactone until Week 12. (NCT03071263)
Timeframe: At week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Group 1 - Patiromer | 126 |
| Group 2 - Placebo | 98 |
"The two baseline potassium subgroups, 4.3-<4.7 mEq/L versus 4.7-5.1 mEq/L, are based on central laboratory data.~If a participant's serum potassium result at baseline was not in one of the two subgroups reported below, the participant's potassium stratum at randomization was used. Therefore, participants with BCSP <4.3 mEq/L or >5.1 mEq/L at baseline (Day 0) have been classified according to their serum potassium values at the Screening period." (NCT03071263)
Timeframe: From baseline to Week 12
| Intervention | mEq/L (Mean) | ||
|---|---|---|---|
| Baseline Central Serum Potassium 4.3-<4.7 mEq/L | Baseline Central Serum Potassium 4.7-<5.1 mEq/L | Overall | |
| Group 1 - Patiromer | 0.16 | -0.09 | 0.02 |
| Group 2 - Placebo | 0.40 | 0.03 | 0.20 |
"QD: Once daily~QOD: Once every other day" (NCT03071263)
Timeframe: From baseline to Week 10
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50 mg QD : Baseline | 50 mg QD : Week 1 | 50 mg QD : Week 2 | 50 mg QD : Week 3 | 50 mg QD : Week 4 | 50 mg QD : Week 6 | 50 mg QD : Week 8 | 50 mg QD : Week 10 | 25 mg QD : Baseline | 25 mg QD : Week 1 | 25 mg QD : Week 2 | 25 mg QD : Week 3 | 25 mg QD : Week 4 | 25 mg QD : Week 6 | 25 mg QD : Week 8 | 25 mg QD : Week 10 | 25 mg QOD : Baseline | 25 mg QOD : Week 1 | 25 mg QOD : Week 2 | 25 mg QOD : Week 3 | 25 mg QOD : Week 4 | 25 mg QOD : Week 6 | 25 mg QOD : Week 8 | 25 mg QOD : Week 10 | |
| Group 1 - Patiromer | 0 | 0 | 0 | 86 | 105 | 106 | 106 | 106 | 147 | 145 | 140 | 49 | 27 | 25 | 26 | 19 | 0 | 1 | 3 | 3 | 3 | 2 | 1 | 2 |
| Group 2 - Placebo | 0 | 0 | 0 | 76 | 94 | 96 | 85 | 80 | 148 | 144 | 142 | 57 | 34 | 28 | 24 | 20 | 0 | 2 | 1 | 2 | 3 | 2 | 4 | 4 |
"Row Titles:~AM: Antihypertensive Medication(s)~New AM: Participants who required additional new antihypertensive medication(s)~Increases to baseline AM: Participants who required increases to baseline antihypertensive medication(s)~Addition new (or increase) AM: Participants who required addition of new antihypertensive medication(s) and/or increases to baseline antihypertensive medications~At any time during the study: During study~While on study medication: On medication" (NCT03071263)
Timeframe: From baseline to Week 12/Early Termination visit
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| New AM : At any time during the study | New AM : On medication | Increases to baseline AM: During study | Increases to baseline AM: On medication | Addition new (or increases) AM: During study | Addition new (or increases) AM : On medication | |
| Group 1 - Patiromer | 0 | 0 | 0 | 0 | 0 | 0 |
| Group 2 - Placebo | 3 | 1 | 2 | 1 | 4 | 2 |
"The titration was performed according to the following criteria: Spironolactone was increased in cases of hypertension, decreased or stopped in cases of hypotension and maintained if the blood pressure results were adequate~The symbols > and ≤ included in the row titles are used to indicate the time interval [>Week1 and ≤Week2 meaning from day 8 until day 14 (included)]." (NCT03071263)
Timeframe: From baseline to Week 12
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Up : ≤Week 1 | Up : >Week 1 and ≤Week 2 | Up : >Week 2 and ≤Week 3 | Up : >Week 3 and ≤Week 4 | Up : >Week 4 and ≤Week 6 | Up : >Week 6 and ≤Week 8 | Up : >Week 8 and ≤Week 10 | Up : >Week 10 and ≤Week 12 | Down : ≤Week 1 | Down : >Week 1 and ≤Week 2 | Down : >Week 2 and ≤Week 3 | Down : >Week 3 and ≤Week 4 | Down : >Week 4 and ≤Week 6 | Down : >Week 6 and ≤Week 8 | Down : >Week 8 and ≤Week 10 | Down : >Week 10 and ≤Week 12 | |
| Group 1 - Patiromer | 0 | 0 | 88 | 27 | 10 | 6 | 6 | 1 | 1 | 2 | 2 | 6 | 8 | 5 | 4 | 3 |
| Group 2 - Placebo | 0 | 0 | 77 | 21 | 11 | 6 | 7 | 0 | 2 | 0 | 2 | 5 | 7 | 8 | 7 | 1 |
"Baseline Central Serum Potassium: BCSP.~The symbols > and ≤ included in the row titles are used to indicate the time interval [>Week1 and ≤Week2 meaning from day 8 until day 14 (included)].~If a participant's serum potassium result at baseline was not in one of the two subgroups reported below, the participant's potassium stratum at randomization was used. Therefore, participants with BCSP <4.3 mEq/L or >5.1 mEq/L at baseline (Day 0) have been classified according to their serum potassium values at the Screening period." (NCT03071263)
Timeframe: From baseline to Week 12
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCSP 4.3-<4.7mEq/L: ≤Week1 | BCSP 4.3-<4.7mEq/L: >Week1 and ≤Week2 | BCSP 4.3-<4.7mEq/L: >Week 2 and ≤Week 3 | BCSP 4.3-<4.7mEq/L: >Week 3 and ≤Week 4 | BCSP 4.3-<4.7mEq/L: >Week 4 and ≤Week 6 | BCSP 4.3-<4.7mEq/L: >Week 6 and ≤Week 8 | BCSP 4.3-<4.7mEq/L: >Week 8 and ≤Week 10 | BCSP 4.3-<4.7mEq/L: > Week 10 and ≤ Week 12 | BCSP 4.7-<5.1 mEq/L: ≤Week 1 | BCSP 4.7-<5.1mEq/L: >Week 1 and ≤Week 2 | BCSP 4.7-<5.1mEq/L: >Week 2 and ≤Week 3 | BCSP 4.7-<5.1mEq/L: >Week 3 and ≤Week 4 | BCSP 4.7-<5.1 mEq/L: >Week 4 and ≤Week 6 | BCSP 4.7-<5.1mEq/L: >Week 6 and ≤Week 8 | BCSP 4.7-<5.1mEq/L: >Week 8 and ≤Week 10 | BCSP 4.7-<5.1mEq/L: >Week 10 and ≤Week 12 | Overall : ≤Week 1 | Overall : > Week 1 and ≤Week 2 | Overall : >Week 2 and ≤Week 3 | Overall : >Week 3 and ≤Week 4 | Overall : >Week 4 and ≤Week 6 | Overall : >Week 6 and ≤Week 8 | Overall : >Week 8 and ≤Week 10 | Overall : >Week 10 and ≤Week 12 | |
| Group 1 - Patiromer | 60 | 57 | 59 | 61 | 61 | 61 | 58 | 61 | 75 | 74 | 74 | 74 | 79 | 74 | 72 | 80 | 135 | 131 | 133 | 135 | 140 | 135 | 130 | 141 |
| Group 2 - Placebo | 62 | 57 | 63 | 60 | 61 | 58 | 58 | 61 | 66 | 65 | 65 | 61 | 64 | 66 | 66 | 65 | 128 | 122 | 128 | 121 | 125 | 124 | 124 | 126 |
"The end of treatment value is defined as the last non-missing value on or prior to the last spironolactone dose date (from End of Treatment - Case report form) + 3 days~LLN=Lower limit of the normal range. ULN=Upper limit of the normal range. EoT=End of Treatment" (NCT03071263)
Timeframe: From Baseline to End of Treatment, up to 12 weeks.
| Intervention | participants (Number) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Magnesium - Baseline Value | Magnesium - Baseline Value | Magnesium - Baseline Value | Magnesium - Baseline Value Normal : EoT Value | Magnesium- Baseline Value Normal: EoT Value Normal | Magnesium - Baseline Value Normal : EoT Value >ULN | Magnesium - Baseline Value >ULN : EoT Value | Magnesium - Baseline Value >ULN : EoT Value Normal | Magnesium - Baseline Value >ULN : EoT Value >ULN | Phosphate - Baseline Value | Phosphate - Baseline Value | Phosphate - Baseline Value | Phosphate - Baseline Value Normal : EoT Value | Phosphate- Baseline Value Normal: EoT Value Normal | Phosphate - Baseline Value Normal : EoT Value >ULN | Phosphate - Baseline Value >ULN : EoT Value | Phosphate - Baseline Value >ULN : EoT Value Normal | Phosphate - Baseline Value >ULN : EoT Value >ULN | Calcium - Baseline Value | Calcium - Baseline Value | Calcium - Baseline Value | Calcium - Baseline Value Normal : EoT Value | Calcium - Baseline Value Normal : EoT Value Normal | Calcium - Baseline Value Normal : EoT Value >ULN | Calcium - Baseline Value >ULN : EoT Value | Calcium - Baseline Value >ULN : EoT Value Normal | Calcium - Baseline Value >ULN : EoT Value >ULN | | |
| Group 1 - Patiromer | 9 | 3 | 0 | 12 | 103 | 6 | 0 | 10 | 3 | 0 | 1 | 0 | 0 | 136 | 2 | 0 | 5 | 2 | 2 | 5 | 0 | 4 | 133 | 0 | 0 | 2 | 0 |
| Group 2 - Placebo | 4 | 8 | 0 | 7 | 109 | 10 | 0 | 6 | 3 | 1 | 3 | 0 | 1 | 125 | 8 | 0 | 4 | 5 | 4 | 1 | 0 | 6 | 133 | 0 | 0 | 1 | 2 |
"Row title:~Participants not completing 12W of study treatment: Participants who had not completed 12 weeks of study treatment." (NCT03071263)
Timeframe: 12 Weeks of Study Treatment
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| 50 mg QD | 25 mg QD | 25 mg QOD | Participants not completing 12W of study treatment | |
| Group 1 - Patiromer | 102 | 22 | 2 | 21 |
| Group 2 - Placebo | 76 | 19 | 3 | 50 |
Number of Cardiovascular deaths defined as death due to myocardial infarction, congestive heart failure, cardiac valvular disease, arrhythmia, sudden death, stroke, or peripheral arterial disease (NCT02285920)
Timeframe: 0 - 40 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 1 |
| Spironolactone 12.5 mg | 0 |
| Spironolactone 25 mg | 2 |
| Spironolactone 50 mg | 1 |
The number of participants who had serum potassium >6.5 mEq/L or serious hyperkalemia was assessed by treatment arm. (NCT02285920)
Timeframe: 0 - 40 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 13 |
| Spironolactone 12.5 mg | 5 |
| Spironolactone 25 mg | 5 |
| Spironolactone 50 mg | 10 |
Hyperkalemia requiring adjustment in dialysate potassium concentration, or discontinuation of study medication (NCT02285920)
Timeframe: 0 - 40 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 13 |
| Spironolactone 12.5 mg | 2 |
| Spironolactone 25 mg | 5 |
| Spironolactone 50 mg | 7 |
Number of patients with serious hyperkalemia requiring hospitalization, emergency/unscheduled dialysis or resin therapy (NCT02285920)
Timeframe: 0 - 40 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 6 |
| Spironolactone 12.5 mg | 2 |
| Spironolactone 25 mg | 0 |
| Spironolactone 50 mg | 7 |
The number of participants who had serum potassium >6.5 mEq/L was assessed by treatment arm. (NCT02285920)
Timeframe: 0 - 40 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Spironolactone 12.5 mg | 4 |
| Spironolactone 25 mg | 4 |
| Spironolactone 50 mg | 8 |
The number of participants experiencing serious hypotension, defined as hypotension requiring hospitalization or ED visit and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). (NCT02285920)
Timeframe: 0 - 40 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| Spironolactone 12.5 mg | 2 |
| Spironolactone 25 mg | 0 |
| Spironolactone 50 mg | 3 |
Tolerability is defined as number of participants who experienced permanent study drug discontinuation or dose reduction. (NCT02285920)
Timeframe: 0 - 36 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 16 |
| Spironolactone 12.5 mg | 5 |
| Spironolactone 25 mg | 6 |
| Spironolactone 50 mg | 8 |
Change in mitral annular E' velocity measured using Tissue Doppler Index (TDI) echocardiography. Efficacy outcomes were considered exploratory with a goal of detecting signals rather than clearly demonstrating efficacy. (NCT02285920)
Timeframe: Baseline to 36 weeks
| Intervention | cm/second (Mean) | ||
|---|---|---|---|
| Baseline MA E' | 36 Week MA E' | Change between baseline - 36 weeks | |
| Placebo | 7.4 | 7.5 | 0.1 |
| Spironolactone 12.5 mg | 7.6 | 7.4 | -0.2 |
| Spironolactone 25 mg | 7.8 | 7.7 | -0.1 |
| Spironolactone 50 mg | 7.0 | 7.3 | 0.3 |
"Secondary outcome measures include other echocardiographic markers of systolic and diastolic function~• Change in left ventricular ejection fraction between Baseline and 36 weeks" (NCT02285920)
Timeframe: Baseline - 36 weeks
| Intervention | percent ejection fraction (Mean) | ||
|---|---|---|---|
| LVEF Baseline | LVEF 36-Week | LVEF Change | |
| Placebo | 68.9 | 70.7 | 1.8 |
| Spironolactone 12.5 mg | 65.9 | 66.9 | 1.0 |
| Spironolactone 25 mg | 66.0 | 65.3 | -0.7 |
| Spironolactone 50 mg | 68.2 | 69.5 | 1.3 |
"Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,~• Change in myocardial strain and strain rate between baseline and 36 weeks" (NCT02285920)
Timeframe: Baseline - 36 weeks
| Intervention | % of myocardial shortening (Mean) | ||
|---|---|---|---|
| LVGLS Baseline | LVGLS 36-week | LVGLS Change | |
| Placebo | -17.2 | -18.1 | -0.8 |
| Spironolactone 12.5 mg | -16.7 | -17.0 | -0.3 |
| Spironolactone 25 mg | -17.2 | -17.0 | 0.2 |
| Spironolactone 50 mg | -17.4 | -18.2 | -0.7 |
"Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,~• E/E' is the ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E')" (NCT02285920)
Timeframe: Baseline - 36 weeks
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| E/E' Baseline | E/E' 36-Week | E/E' Change | |
| Placebo | 10.7 | 11.5 | 0.9 |
| Spironolactone 12.5 mg | 11.8 | 12.2 | 0.4 |
| Spironolactone 25 mg | 9.2 | 10.6 | 1.4 |
| Spironolactone 50 mg | 12.5 | 11.9 | -0.6 |
"Secondary outcome measures include other echocardiographic markers of systolic and diastolic function,~• Change in left ventricular mass index (LVMI) between baseline and 36 weeks" (NCT02285920)
Timeframe: Baseline - 36 weeks
| Intervention | g/m^2 (Mean) | ||
|---|---|---|---|
| LVMI Baseline | LVMI 36-Week | LVMI Change | |
| Placebo | 105.2 | 94.8 | -10.4 |
| Spironolactone 12.5 mg | 115.5 | 104.6 | -10.9 |
| Spironolactone 25 mg | 116.4 | 109.1 | -7.3 |
| Spironolactone 50 mg | 106.3 | 96.5 | -9.8 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) |
|---|---|
| Eplerenone: Double-blind Phase | 288 |
| Placebo: Double-blind Phase | 392 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010)
| Intervention | participants (Number) |
|---|---|
| Eplerenone: Double-blind Phase | 249 |
| Placebo: Double-blind Phase | 356 |
Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 408 | 463 |
| Placebo: Double-blind Phase | 491 | 552 |
Death due to any cause. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 171 | 205 |
| Placebo: Double-blind Phase | 213 | 253 |
Death due to any cause or hospitalization due to any cause. Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 462 | 530 |
| Placebo: Double-blind Phase | 569 | 636 |
Death due to any cause or first of occurrence HF hospitalization. HF hospitalization is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 270 | 311 |
| Placebo: Double-blind Phase | 376 | 418 |
First occurrence of CV hospitalization. CV hospitalization is defined as hospitalization due to HF (first or subsequent), acute myocardial infarction, angina pectoris (unstable), cardiac arrhythmia (atrial fibrillation [AF], atrial flutter, supraventricular arrhythmias, or ventricular arrhythmias), stroke/CVA, other CV reasons (such as hypotension or peripheral vascular disease), implantation of a cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) with CV event as the primary reason for hospitalization as determined by endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 304 | 346 |
| Placebo: Double-blind Phase | 399 | 439 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 147 | 178 |
| Placebo: Double-blind Phase | 185 | 215 |
(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 45 | 49 |
| Placebo: Double-blind Phase | 33 | 40 |
(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 21 | 24 |
| Placebo: Double-blind Phase | 26 | 31 |
First occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 164 | 186 |
| Placebo: Double-blind Phase | 253 | 277 |
Death due to HF or first occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 170 | 194 |
| Placebo: Double-blind Phase | 262 | 287 |
First occurrence of hospitalization due to hyperkalemia. Hospitalization due to hyperkalemia is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization as determined by endpoint committee adjudicator. Hyperkalemia is defined as serum potassium level greater than (>) 5.5 milliequivalents per liter (mEq/L). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 4 | 4 |
| Placebo: Double-blind Phase | 3 | 3 |
First occurrence of hospitalization due to worsening renal function. Hospitalization due to worsening renal function is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization as determined by endpoint committee adjudicator. Worsening renal function is defined as doubling of serum creatinine level from baseline level. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 9 | 10 |
| Placebo: Double-blind Phase | 8 | 10 |
First occurrence of implantation of cardiac defibrillator (ICD). ICD is an electronic device capable of monitoring the heart rhythm. When the heart is beating normally, the device remains inactive. If the heart develops a life-threatening tachycardia, the ICD delivers electrical shocks to the heart to terminate the abnormal rhythm and return the heart rhythm to normal. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 61 | 76 |
| Placebo: Double-blind Phase | 59 | 78 |
First occurrence of implantation of resynchronization device. CRT is use of a specialized pacemaker to re-coordinate the action of the right and left ventricles in heart failure. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 33 | 45 |
| Placebo: Double-blind Phase | 41 | 53 |
New onset of atrial fibrillation or flutter is defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization, where atrial fibrillation was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 950, 937) | Up to 59.5 months (complete DB) (n= 956, 940) | |
| Eplerenone: Double-blind Phase | 32 | 41 |
| Placebo: Double-blind Phase | 52 | 59 |
The definition of new onset diabetes mellitus is the diagnosis of diabetes mellitus in a participant after randomization, when DM was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 904, 973) | Up to 59.5 months (complete DB) (n= 907, 975) | |
| Eplerenone: Double-blind Phase | 34 | 42 |
| Placebo: Double-blind Phase | 40 | 47 |
N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute and chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Baseline and Day 90
| Intervention | Percentage of participants (Number) |
|---|---|
| Eplerenone (INSPRA®) | 37.2 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 30.9 |
| Finerenone (BAY94-8862) 5-10 mg OD | 32.5 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 37.3 |
| Finerenone (BAY94-8862) 10-20 mg OD | 38.8 |
| Finerenone (BAY94-8862) 15-20 mg OD | 34.2 |
(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | millimeter for mercury (mmHg) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Day 7 | Day 14 | Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 71.633 | -1.351 | -3.442 | -0.503 | -0.613 | -0.716 | -3.185 | -1.218 |
| Finerenone (BAY94-8862) 10-20 mg OD | 70.343 | -0.738 | -2.387 | -0.094 | 0.17 | -0.545 | -2.96 | -0.298 |
| Finerenone (BAY94-8862) 15-20 mg OD | 71.145 | -1.166 | -0.625 | -1.163 | -0.575 | -0.877 | -0.083 | -0.172 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 71.044 | -1.693 | -0.537 | 0.146 | -0.199 | -0.106 | 0.868 | 0.696 |
| Finerenone (BAY94-8862) 5-10 mg OD | 71.442 | -2.143 | 1.608 | -0.845 | -2.144 | -1.738 | -2.194 | -0.444 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 70.61 | 0.013 | -0.083 | -0.068 | -0.85 | -1.121 | 4.101 | -1.16 |
EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L): participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state. (NCT01807221)
Timeframe: Baseline, Day 30, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 30 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 0.58 | 0.06 | 0.08 | -0.12 | 0.06 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0.56 | 0.06 | 0.1 | -0.05 | 0.07 |
| Finerenone (BAY94-8862) 15-20 mg OD | 0.59 | 0.02 | 0.06 | 0 | 0.04 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 0.59 | 0.02 | 0.03 | -0.06 | 0.01 |
| Finerenone (BAY94-8862) 5-10 mg OD | 0.62 | 0.02 | 0.04 | -0.09 | 0.01 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 0.58 | 0.07 | 0.08 | -0.1 | 0.08 |
(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Beats per minute (Beats/min) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Day 7 | Day 14 | Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 74.957 | -0.8 | -3.109 | 0.294 | 0.297 | -0.189 | -2.278 | -1.281 |
| Finerenone (BAY94-8862) 10-20 mg OD | 73.852 | -0.548 | 0.423 | -0.802 | 0.192 | -0.71 | 4.733 | 0.834 |
| Finerenone (BAY94-8862) 15-20 mg OD | 74.329 | -1.176 | -3.969 | -1.633 | -1.608 | -1.145 | -2.072 | -1.317 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 73.369 | 1.073 | 0.599 | 1.064 | -0.975 | -1.647 | -1.424 | -2.057 |
| Finerenone (BAY94-8862) 5-10 mg OD | 72.681 | -0.63 | 1.842 | 0.435 | -1.741 | -2.89 | -0.222 | -0.626 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 74.184 | -0.719 | -1.324 | -0.349 | -2.318 | -2.212 | 1.101 | -1.326 |
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was the leading health related quality of life measure for subjects with CHF. KCCQ was a 23 item questionnaire that independently measures the impact of subjects HF, or its treatment, on 7 distinct domains: self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Results from the total symptom summary score are presented. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. In the below table, categorical data represents change from baseline data at respective time points. (NCT01807221)
Timeframe: Baseline, Day 30 and Day 90
| Intervention | Scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Day 30 | Day 90 | |
| Eplerenone (INSPRA®) | 43.7 | 20.5 | 24.3 |
| Finerenone (BAY94-8862) 10-20 mg OD | 42.3 | 24.9 | 28.3 |
| Finerenone (BAY94-8862) 15-20 mg OD | 43.2 | 20.6 | 22.2 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 42.8 | 18.2 | 21.3 |
| Finerenone (BAY94-8862) 5-10 mg OD | 45.4 | 19.3 | 24.5 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 42.1 | 23 | 29.3 |
(NCT01807221)
Timeframe: Baseline, Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | millimoles per liter (mmol/L) (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 4.159 | 0.057 | 0.179 | 0.307 | 0.117 |
| Finerenone (BAY94-8862) 10-20 mg OD | 4.131 | 0.21 | 0.274 | 0.275 | 0.175 |
| Finerenone (BAY94-8862) 15-20 mg OD | 4.117 | 0.193 | 0.216 | 0.245 | 0.036 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 4.081 | 0.135 | 0.091 | 0.184 | 0.226 |
| Finerenone (BAY94-8862) 5-10 mg OD | 4.211 | 0.075 | 0.131 | 0.153 | 0.054 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 4.174 | 0.085 | 0.171 | 0.164 | 0.05 |
(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | millimeter of mercury (mmHg) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Day 7 | Day 14 | Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 120.554 | -0.541 | -3.442 | 0.067 | 0.684 | -0.967 | -2.991 | 0.188 |
| Finerenone (BAY94-8862) 10-20 mg OD | 116.024 | 0.162 | -3.099 | 1.786 | 0.981 | 1.216 | -2.32 | 2.041 |
| Finerenone (BAY94-8862) 15-20 mg OD | 116.941 | -0.546 | -2.906 | 0.899 | 0.667 | 0.956 | -0.028 | 3.037 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 119.492 | -3.178 | -4.488 | -0.824 | 0.337 | 0.922 | -0.41 | 2.869 |
| Finerenone (BAY94-8862) 5-10 mg OD | 118.498 | -2.565 | 4.142 | -0.367 | -1.249 | 0.047 | -2.167 | 1.95 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 119.087 | 0.568 | 1.241 | 0.374 | -1.811 | -0.664 | 9.391 | -0.928 |
Hospitalizations were defined as any unplanned admission to hospital, i.e. completion of hospital admission procedures and one overnight [i.e. date change] stay or until the death of subject occurred. Hospitalizations and deaths were classified by 2 primary categories: CV and non-CV. The pre-specified subcategories for CV hospitalizations were as follows: 1. Worsening heart failure, 2.Acute myocardial infarction, 3. Arrhythmia, 4.Transient ischemic attack and stroke, 5. Other CV hospitalizations. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 28 | 43 | 45 | 56 |
| Finerenone (BAY94-8862) 10-20 mg OD | 7 | 15 | 22 | 27 |
| Finerenone (BAY94-8862) 15-20 mg OD | 15 | 23 | 28 | 34 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 23 | 33 | 35 | 43 |
| Finerenone (BAY94-8862) 5-10 mg OD | 14 | 23 | 26 | 38 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 8 | 21 | 29 | 36 |
Death due to any cause include cardiovascular (CV) death and Non-CV death. Non-CV death was classified by 2 subcategories: non-malignant causes and malignant causes. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 6 | 7 | 9 | 15 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0 | 0 | 1 | 2 |
| Finerenone (BAY94-8862) 15-20 mg OD | 2 | 4 | 5 | 8 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 5 | 7 | 10 | 16 |
| Finerenone (BAY94-8862) 5-10 mg OD | 1 | 3 | 4 | 7 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 1 | 2 | 4 | 11 |
Emergency presentations for WCHF were defined as newly developing signs and symptoms of WCHF after start of treatment with study drug, requiring an additional emergency presentation to hospital and IV treatment with diuretics and/or positive inotropic agents. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 21 | 35 | 37 | 47 |
| Finerenone (BAY94-8862) 10-20 mg OD | 7 | 14 | 18 | 26 |
| Finerenone (BAY94-8862) 15-20 mg OD | 15 | 22 | 28 | 34 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 19 | 30 | 32 | 40 |
| Finerenone (BAY94-8862) 5-10 mg OD | 12 | 20 | 22 | 30 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 9 | 17 | 24 | 30 |
B-type natriuretic peptide (BNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 0.925 | 0.783 | 0.723 | 0.896 | 0.795 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0.852 | 0.711 | 0.706 | 0.848 | 0.729 |
| Finerenone (BAY94-8862) 15-20 mg OD | 0.879 | 0.824 | 0.771 | 1.044 | 0.852 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 0.944 | 0.864 | 0.813 | 1.104 | 0.815 |
| Finerenone (BAY94-8862) 5-10 mg OD | 0.878 | 0.854 | 0.839 | 1.006 | 0.886 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 0.832 | 0.79 | 0.719 | 0.884 | 0.726 |
N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 0.883 | 0.749 | 0.688 | 0.948 | 0.747 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0.822 | 0.748 | 0.728 | 1.133 | 0.746 |
| Finerenone (BAY94-8862) 15-20 mg OD | 0.921 | 0.829 | 0.771 | 0.965 | 0.849 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 0.98 | 0.822 | 0.789 | 1.369 | 0.747 |
| Finerenone (BAY94-8862) 5-10 mg OD | 0.874 | 0.814 | 0.765 | 1.267 | 0.887 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 0.888 | 0.81 | 0.783 | 0.927 | 0.809 |
19 reviews available for spironolactone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Management of hypertension in advanced kidney disease.
Topics: Blood Pressure; Chlorthalidone; Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Antag | 2022 |
Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridine | 2022 |
Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review.
Topics: Biomarkers; Calcium Phosphates; Citrates; Dialysis Solutions; Humans; Magnesium; Renal Insufficiency | 2022 |
Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Heart Failure; Humans; Hyperkalemia; | 2022 |
Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Glycated Hemoglobin; Heart Failure; H | 2022 |
Hypertension in chronic kidney disease-treatment standard 2023.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hyperkalemia; Hypertension; Mineral | 2023 |
Evolution of Patiromer Use: a Review.
Topics: Humans; Hyperkalemia; Polymers; Potassium; Renal Insufficiency, Chronic; Spironolactone | 2020 |
Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor A | 2021 |
Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda.
Topics: Blood Pressure; Humans; Hypertension; Potassium; Prevalence; Renal Insufficiency, Chronic; Spironola | 2020 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; | 2021 |
[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nep | 2019 |
Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetic Ne | 2014 |
Aldosterone and volume management in hypertensive heart disease.
Topics: Aldosterone; Area Under Curve; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Mineraloc | 2014 |
Impact of aldosterone on osteoinductive signaling and vascular calcification.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Humans; Hyperphosphatemia; Mice; Mineralocorticoid Re | 2014 |
Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.
Topics: Aldosterone; Blood Pressure; Disease Progression; Eplerenone; Heart Failure; Humans; Kidney Failure, | 2016 |
Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016.
Topics: Age Factors; Aldosterone; Blood Pressure Monitoring, Ambulatory; Comorbidity; Diabetes Mellitus; Hum | 2016 |
Update in Hypertension Therapy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2016 |
Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?
Topics: Animals; Aspirin; Humans; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Spir | 2009 |
Evaluation and pharmacologic approach to patients with resistant hypertension.
Topics: Antihypertensive Agents; Diuretics; Drug Resistance; Drug Therapy, Combination; Humans; Hypertension | 2012 |
30 trials available for spironolactone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Protective effects of spironolactone on vascular calcification in chronic kidney disease.
Topics: Aldosterone; Alkaline Phosphatase; Animals; Aorta; Biomarkers; Cholecalciferol; Core Binding Factor | 2021 |
Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Hum | 2022 |
Efficacy and safety of a low-sodium diet and spironolactone in patients with stage 1-3a chronic kidney disease: a pilot study.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diet, Sodiu | 2022 |
Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial.
Topics: Humans; Hypertension; Polymers; Renal Insufficiency, Chronic; Spironolactone | 2021 |
Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Humans; Hyperkalemia; Mineralocorticoid Receptor Anta | 2023 |
Effect of spironolactone on the progression of coronary calcification in peritoneal dialysis patients: a pilot study.
Topics: Aged; Calcium; Cholesterol, LDL; Disease Progression; Female; Follow-Up Studies; Humans; Lost to Fol | 2019 |
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperkalemia | 2019 |
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
Topics: Aged; Amber; Female; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Mineralocorticoid Rece | 2020 |
Evolution of Patiromer Use: a Review.
Topics: Humans; Hyperkalemia; Polymers; Potassium; Renal Insufficiency, Chronic; Spironolactone | 2020 |
Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker.
Topics: Aged; Atrial Fibrillation; Catheter Ablation; Combined Modality Therapy; Double-Blind Method; Echoca | 2018 |
Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease.
Topics: Aged; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Hum | 2018 |
Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
Topics: Aged; Chelating Agents; Clinical Trials as Topic; Double-Blind Method; Drug Resistance; Drug Therapy | 2018 |
Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study.
Topics: Blood Pressure; Demography; Eplerenone; Female; Heart Rate; Humans; Male; Middle Aged; Mineralocorti | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; K | 2013 |
Spironolactone increases serum uric acid levels in patients with chronic kidney disease.
Topics: Diuretics; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Renal | 2014 |
Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare t
Topics: Cardiovascular Diseases; Clinical Protocols; Disease Progression; Drug Administration Schedule; Fema | 2014 |
Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diuretics; Dose-Res | 2014 |
Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.
Topics: Adipose Tissue; Aged; Aldosterone; Amidohydrolases; Animals; Arginine; Cell Nucleus; Cytochrome P-45 | 2015 |
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Creatinine; Double-Blind Method; Eplerenone; Fema | 2014 |
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mine | 2015 |
Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; England; Feasibility Studies; Female; Humans; Ma | 2016 |
A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
Topics: Adult; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; H | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease.
Topics: Adult; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studie | 2009 |
The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Female; Humans; H | 2010 |
The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2012 |
The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?.
Topics: Adult; Albuminuria; Amides; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Comorbidity | 2012 |
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; D | 2006 |
Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2006 |
The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction.
Topics: Aged; Algorithms; Blood Urea Nitrogen; Creatinine; Cyclic GMP; Diuresis; Drug Administration Schedul | 2008 |
42 other studies available for spironolactone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks.
Topics: Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Hyperkalemia; Male; Mineralocorticoid Rece | 2022 |
Zinc oxide nanoparticles and spironolactone-enhanced Nrf2/HO-1 pathway and inhibited Wnt/β-catenin pathway in adenine-induced nephrotoxicity in rats.
Topics: Adenine; Animals; Anti-Inflammatory Agents; Antioxidants; beta Catenin; Male; Nanoparticles; NF-E2-R | 2022 |
Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Topics: Bayes Theorem; Cardiovascular Diseases; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2023 |
Basigin is released in extracellular vesicles derived from the renal tubular epithelium in response to albuminuria.
Topics: Adult; Albuminuria; Basigin; Epithelium; Extracellular Vesicles; Humans; Proteinuria; Renal Insuffic | 2023 |
Pharmacological Management of Resistant Hypertension in Moderate-to-advanced CKD: A Glance at Novel Non-steroidal MRAs.
Topics: Heart Failure; Humans; Hypertension; Renal Insufficiency, Chronic; Spironolactone | 2023 |
Caring for individuals with hypertension in CKD, especially those with low education.
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Renal Insufficiency, Chronic; Spirono | 2019 |
Spironolactone plus patiromer: proceed with caution.
Topics: Amber; Double-Blind Method; Humans; Hypertension; Polymers; Renal Insufficiency, Chronic; Spironolac | 2019 |
An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?
Topics: Adult; Humans; Hyperaldosteronism; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Renal | 2020 |
Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users.
Topics: Adult; Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dise | 2020 |
Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study).
Topics: Aged; Cardiomyopathies; Case-Control Studies; Diarrhea; Diuretics; Female; Heart Failure; Humans; Hy | 2020 |
Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER.
Topics: Amber; Cost-Benefit Analysis; Double-Blind Method; Humans; Hypertension; Polymers; Renal Insufficien | 2020 |
Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease.
Topics: Aged; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hyperkalemia; Male; Rena | 2021 |
Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes.
Topics: Diabetes Complications; Humans; Hypertension; Polymers; Renal Insufficiency, Chronic; Spironolactone | 2021 |
Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diuretics; Female; Follow-Up Studies; Heart Failure; | 2017 |
Hyperkalemia and cardiac arrest associated with glucose replacement in a patient on spironolactone.
Topics: Aged; Diabetes Mellitus; Emergency Treatment; Female; Glucose; Heart Arrest; Humans; Hyperkalemia; R | 2017 |
Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Biomarkers; Blood Pressure; Cardiovascular Diseases; Ch | 2017 |
Nephrotoxicity Induced by Cisplatin Intake in Experimental Rats and Therapeutic Approach of Using Mesenchymal Stem Cells and Spironolactone.
Topics: Allografts; Animals; Cisplatin; Fibrosis; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal S | 2018 |
Preoperative aldosterone receptor blockade and outcomes of cardiac surgery in patients with chronic kidney disease
.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Cardiac Output, Low; Cardiac Surgical Procedures; Fema | 2018 |
Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease.
Topics: Diabetes Mellitus; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renal Insufficienc | 2017 |
Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
Topics: Administration, Oral; Aldosterone; Animals; Benzoates; Cell Line, Tumor; Dose-Response Relationship, | 2018 |
Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study.
Topics: Aged; Aged, 80 and over; Biomarkers; Denmark; Female; Heart Failure; Humans; Hyperkalemia; Incidence | 2018 |
Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation.
Topics: Acute Kidney Injury; Animals; Delayed-Action Preparations; Disease Models, Animal; Disease Progressi | 2019 |
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Deprescriptions; Disease Progression; | 2019 |
Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients: Mind the Gap of Biological Monitoring!
Topics: Biological Monitoring; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renal Insuffic | 2019 |
Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study.
Topics: Adult; Aged; Comorbidity; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypertension; Lo | 2019 |
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; C | 2013 |
Eplerenone: another drug to add to the mix?
Topics: Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Male; Mineralocorticoid Re | 2013 |
The authors reply.
Topics: Acute Kidney Injury; Animals; Ischemia; Male; Renal Insufficiency, Chronic; Spironolactone | 2013 |
How to confirm the specific effect of spironolactone in chronic kidney disease caused by ischemic acute kidney injury?
Topics: Acute Kidney Injury; Animals; Ischemia; Male; Renal Insufficiency, Chronic; Spironolactone | 2013 |
Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 2013 |
Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease.
Topics: Aged; Aldosterone; Case-Control Studies; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meie | 2014 |
Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
Topics: Aged; Antihypertensive Agents; Female; Humans; Hyperkalemia; Hypertension; Incidence; Kidney Functio | 2014 |
Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
Topics: Adenine; Animals; Aorta, Abdominal; Aortic Diseases; Apoptosis; Biomarkers; Disease Models, Animal; | 2015 |
Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Anti-Arrhythmia Agents | 2015 |
Effects of Treating Primary Aldosteronism on Renal Function.
Topics: Adrenalectomy; Adult; Aldosterone; Female; Glomerular Filtration Rate; Humans; Hyperaldosteronism; M | 2017 |
Serum Potassium Levels and Outcome in Patients With Chronic Heart Failure.
Topics: Aged; Aged, 80 and over; Chronic Disease; Cohort Studies; Diuretics; Female; Heart Failure; Humans; | 2016 |
Aldosterone receptor antagonists: effective but often forgotten.
Topics: Eplerenone; Female; Follow-Up Studies; Humans; Hypertension; Middle Aged; Mineralocorticoid Receptor | 2010 |
[Aldosterone exacerbates chronic renal insufficiency].
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2011 |
Upright T waves in lead aVR are associated with cardiac death or hospitalization for heart failure in patients with a prior myocardial infarction.
Topics: Age Factors; Aged; Anterior Wall Myocardial Infarction; Chi-Square Distribution; Death, Sudden, Card | 2012 |
Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury.
Topics: Acute Kidney Injury; Animals; Collagen Type I; Disease Models, Animal; Diuretics; Dose-Response Rela | 2013 |
Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice.
Topics: Aldosterone; Animals; Cell Differentiation; Cells, Cultured; Fibroblast Growth Factor-23; Fibroblast | 2013 |
Use of antagonists of aldosterone in patients with chronic kidney disease: Potential advantages and risks.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropa | 2006 |